Journal
CIRCULATION RESEARCH
Volume 115, Issue 1, Pages 165-175Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.113.301141
Keywords
hypertension; pulmonary; leukotriene B4
Funding
- ANR (French National Research Agency) Starting Grant [ANR-12-JSV1-0004-01]
- National Institutes of Health grants [HL082662, NHLBI-HV-10-05]
- Agence Nationale de la Recherche (ANR) [ANR-12-JSV1-0004] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension. The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed. Pre-clinical studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed. In addition, we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development. We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available